Henry Schein Inc.
HSICBusiness Model
source: coverage-next-full ticker: HSIC step: "01" title: Business Overview — Segments, Model, Strategy created: 2026-05-29
Step 01: Business Overview — Henry Schein, Inc.
Company Description
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental and medical practitioners. Founded in 1932 in Flushing, New York, the company serves approximately 1 million customers worldwide through a combination of physical product distribution, digital commerce, and software-enabled practice management tools.
The company operates a "value-added distribution" model — going beyond simple product logistics to embed software, financial services, and clinical education into customer workflows, creating stickiness well beyond what a commodity distributor enjoys.
Business Segments
1. Dental Segment (~75% of Revenue)
The Dental segment provides dental practitioners with consumable products, dental equipment, and technology/software solutions. Key sub-verticals:
Consumables (~50% of dental revenue)
- Infection control products (gloves, masks, barriers)
- Impression materials and restorative products
- Anesthetics, cements, and bonding agents
- Lab products and small hand instruments
- Prophylaxis products (prophy paste, polishing cups)
Equipment (~20% of dental revenue)
- Dental chairs, delivery systems, lighting
- Digital imaging (x-ray, CBCT scanners, intraoral cameras)
- Sterilization equipment
- CAD/CAM systems (digital dentistry)
Technology/Software (~30% of dental revenue)
- Henry Schein One (HS1) — umbrella brand for practice management software
- Dentrix — dominant US dental practice management software (300,000+ practitioners)
- Eaglesoft — second major PM platform (acquired from Patterson-era competitor)
- Curve Dental — cloud-native practice management (cloud-first practices)
- Lighthouse 360 — patient communication and recall automation
- Carestream Dental (imaging software components)
- Revenue cycle management (RCM) for dental practices
- Patient engagement and teledentistry tools
Geographic Mix (Dental)
- North America: ~55% of dental segment
- International: ~45% of dental segment (Europe, Australia, Canada primary markets)
2. Medical Segment (~25% of Revenue)
The Medical segment serves office-based physician practices, community health centers, and ambulatory care facilities. Key products:
- Injectable medications and vaccines
- Wound care products
- Diagnostic supplies (glucose monitoring, diagnostic kits)
- Surgical instruments and PPE
- Rehabilitation products
- AED devices and emergency products
Key customers: Primary care physicians, urgent care clinics, community health centers, surgical centers, long-term care facilities.
Competitive position: Top-3 distributor to office-based physicians in the US. Competes primarily with McKesson Medical, Cardinal Health, and Medline.
Business Model
Henry Schein's distribution model operates on two economic pillars:
Product Distribution: High-SKU (~300,000+ SKUs), high-touch distribution to fragmented small-practice customers. HSIC differentiates through field sales representatives ("field sales consultants") who call on dental offices, cross-sell products, and provide clinical education. The sales force creates switching friction beyond what a pure e-commerce competitor can replicate.
Software/Technology: Henry Schein One (HSOne) generates recurring SaaS-like revenue from subscription-based practice management software. This segment enjoys ~80% gross margins vs. ~30% for consumables distribution — the strategic prize driving HSIC's technology investment.
Key Operating Statistics (FY2023)
| Metric | Value |
|---|---|
| Net Revenue | ~$12.35B |
| Countries Operated | 32+ |
| Customers Served | ~1 million |
| Team Schein Members (employees) | ~24,000 |
| Dental Software Users (Dentrix/Eaglesoft) | ~300,000+ practitioners |
| Field Sales Reps | ~5,000+ |
| SKUs Offered | ~300,000+ |
Strategic Priorities
DSO (Dental Service Organization) Penetration: The US dental market is consolidating around DSOs (multi-location dental chains like Heartland Dental, Aspen Dental, Pacific Dental). HSIC has a dedicated DSO sales team and is the preferred distributor for many of the largest DSOs. DSOs are credit-worthy, large-volume purchasers with lower cost-to-serve.
Henry Schein One Expansion: Growing HSOne from point-of-sale practice management to a full "dental operating system" — incorporating patient financing, teledentistry, insurance eligibility, and revenue cycle management. HSOne commands a premium ASP and better margin than product distribution.
Specialty Dental Growth: Orthodontics (clear aligners), implants, and oral surgery are the fastest-growing segments of the dental market. HSIC has been acquiring and investing in specialty distribution and software.
International Expansion: International dental is ~45% of dental segment revenue. Key markets include Germany, UK, Netherlands, France, Australia. Opportunities in emerging dental markets (Brazil, China through partnerships).
Acquisitions: HSIC has historically made 5-10 bolt-on acquisitions per year, primarily in dental distribution, dental software, and specialty products. The 2022 acquisition of Shield Healthcare (home health supplies) and various dental software tuck-ins are examples.
Corporate Governance Overview
- Headquarters: 135 Duryea Road, Melville, New York 11747
- CEO: Stanley Bergman (Chairman & CEO since 1989 — over 35 years)
- CFO: Ronald South (appointed 2022; previously corporate controller)
- Listed: NASDAQ (HSIC)
- Index Membership: S&P 500, NASDAQ-100 (removed 2024)
- Shares Outstanding: ~135 million diluted (FY2024)
Financial Snapshot
source: coverage-next-full ticker: HSIC step: "04" title: Financial Snapshot — 3-Year P&L, Key Metrics created: 2026-05-29
Step 04: Financial Snapshot — 3-Year P&L Summary
Income Statement Summary
| Metric | FY2021 | FY2022 | FY2023 | 3-Yr CAGR |
|---|---|---|---|---|
| Net Revenue | $12,437M | $12,630M | $12,349M | -0.4% |
| Cost of Sales | $8,006M | $8,163M | $7,994M | |
| Gross Profit | $4,431M | $4,467M | $4,355M | -0.9% |
| Gross Margin | 35.6% | 35.4% | 35.3% | |
| Operating Expenses (SG&A) | $3,190M | $3,290M | $3,420M | |
| Restructuring/Cyber Costs | — | — | ~$50M | |
| Operating Income (EBIT) | $1,241M | $1,177M | $885M | -16.2% |
| EBIT Margin | 9.98% | 9.32% | 7.17% | |
| Adj. EBIT (ex-cyber/one-time) | ~$1,241M | ~$1,177M | ~$1,010M | |
| Adj. EBIT Margin | 9.98% | 9.32% | 8.18% | |
| Net Interest Expense | $(62)M | $(86)M | $(121)M | |
| Pre-Tax Income | $1,179M | $1,091M | $764M | |
| Income Tax Expense | $264M | $246M | $191M | |
| Effective Tax Rate | 22.4% | 22.5% | 25.0% | |
| Net Income (GAAP) | $835M | $734M | $478M | -24.4% |
| Net Income Margin | 6.7% | 5.8% | 3.9% | |
| Adj. Net Income (ex-one-time) | ~$835M | ~$734M | ~$640M | |
| Diluted EPS (GAAP) | $5.79 | $5.24 | $3.51 | |
| Adj. Diluted EPS | ~$5.79 | ~$5.58 | ~$4.72 | |
| Diluted Shares Outstanding | 144.2M | 140.1M | 136.2M |
Note: FY2023 GAAP results were heavily impacted by the October 2023 cybersecurity incident. Adjusted figures exclude approximately $150-175M in cyber-related costs (lost revenue impact, recovery expenses, legal/insurance accruals). The effective tax rate was also higher in FY2023 due to unfavorable discrete items.
Adjusted EPS Bridge (FY2022 → FY2023)
| Factor | EPS Impact |
|---|---|
| FY2022 Adj. EPS baseline | $5.58 |
| Organic volume/price improvement | +$0.30 |
| Cyber incident (lost revenue + costs) | -$(1.00) |
| Higher interest expense | -$(0.25) |
| Share count reduction (buybacks) | +$0.12 |
| FX headwind | -$(0.03) |
| FY2023 Adj. EPS | ~$4.72 |
Key Profitability Metrics
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Gross Margin | 35.6% | 35.4% | 35.3% |
| EBIT Margin (adj.) | 9.98% | 9.32% | 8.18% |
| EBITDA Margin (adj.) | 11.5% | 10.8% | 9.7% |
| Net Margin (adj.) | 6.7% | 5.8% | 5.2% |
| FCF Margin | ~4.0% | ~3.5% | ~2.5% |
EBITDA Build
| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Operating Income (Adj.) | $1,241M | $1,177M | $1,010M |
| D&A | $185M | $200M | $210M |
| Stock-Based Compensation | $65M | $70M | $75M |
| Adj. EBITDA | ~$1,491M | ~$1,447M | ~$1,295M |
| Adj. EBITDA Margin | 12.0% | 11.5% | 10.5% |
Revenue Growth Components
| Year | Total Growth | Price/Mix | Volume | FX | M&A |
|---|---|---|---|---|---|
| FY2021 | +18.5% | +3% | +12% | +1% | +2.5% |
| FY2022 | +1.5% | +2% | +1% | -2% | +0.5% |
| FY2023 | -2.2% | +1% | -3% | -1% | +0.8% |
Segment Profitability (Est.)
| Segment | Revenue | Operating Income | Operating Margin |
|---|---|---|---|
| Dental (FY2023) | ~$9.1B | ~$850M | ~9.3% |
| Medical (FY2023) | ~$3.1B | ~$250M | ~8.1% |
| Corporate | — | ~$(90M) | — |
| Total (Adj.) | ~$12.35B | ~$1,010M | ~8.2% |
Note: Dental segment carries the software/technology sub-segment which has margins of 25-30%+ and disproportionately supports the blended dental margin.
Margins vs. Peers
| Company | Gross Margin | EBIT Margin | Context |
|---|---|---|---|
| HSIC | 35.3% | 8.2% (adj.) | Value-added dental dist. + software |
| Patterson (PDCO) | 28.0% | 6.0% | Dental + animal health distributor |
| McKesson (MCK) | 5.0% | 2.5% | Drug distributor (lower margin by nature) |
| Cardinal Health (CAH) | 3.8% | 1.8% | Drug distributor |
| AmerisourceBergen (ABC) | 3.5% | 1.7% | Drug distributor |
HSIC's gross margin premium (35% vs. 28% for PDCO, >30% vs. drug distributors) reflects:
- Higher-value dental products (materials vs. pills)
- Software revenue mix (~15% of revenue at 70%+ gross margins)
- Value-added services bundled into pricing
Working Capital Dynamics
| Metric | FY2022 | FY2023 |
|---|---|---|
| Days Sales Outstanding (DSO) | ~42 days | ~44 days |
| Days Inventory Outstanding (DIO) | ~38 days | ~40 days |
| Days Payable Outstanding (DPO) | ~48 days | ~50 days |
| Cash Conversion Cycle (CCC) | ~32 days | ~34 days |
HSIC's cash conversion cycle is modest for a distributor, though the cyber incident slightly elevated DSO as customers took longer to pay during the disruption period.
Forward Estimates (FY2024E)
| Metric | FY2024E (Consensus) |
|---|---|
| Revenue | ~$12.8B |
| Adj. EBIT | ~$830M-860M |
| Adj. EBIT Margin | ~6.5-6.7% |
| Adj. EPS | ~$4.60-4.90 |
| Adj. EBITDA | ~$1,050-1,080M |
Note: FY2024 consensus assumes continued cyber recovery, some normalization of legal/insurance costs related to cyber, and gradual HSOne subscription growth. The margin outlook is weaker than FY2022 as the company invests in technology/DSO sales infrastructure.
Recent Catalysts
source: coverage-next-full ticker: HSIC step: "12" title: Catalysts — Near-Term Events and Bull/Bear Framework created: 2026-05-29
Step 12: Catalysts
Near-Term Catalysts (Next 12-18 Months)
Catalyst 1: Resolution of Cyber Legal Matters
Timeline: Q2 2025 – Q4 2026 What to watch: Class action lawsuit settlements, HHS/OCR resolution, state AG outcomes Bull case outcome: HSIC settles all cyber-related litigation and regulatory matters within existing insurance coverage (~$150M); total above-insurance out-of-pocket cost <$50M. Removes the "unknown liability" overhang that has suppressed the valuation multiple. Bear case outcome: HHS levies major HIPAA penalties; class action settles for $200M+ above insurance coverage; ongoing legal costs drag EPS by $0.50+ through 2027. Probability of bull outcome: 55% (insurance coverage appears adequate for base case) EPS impact: +$0.40-0.60 if resolved favorably (multiple expansion + cost removal)
Catalyst 2: Q4 2024 / FY2024 Earnings (Easy Cyber Comp)
Timeline: Q1 2025 earnings release What to watch: Q4 2024 dental revenue vs. Q4 2023 devastated comp; recovery in DSO customer relationships Expected outcome: Q4 2024 organic dental growth of 8-12% (vs. -24.8% in Q4 2023); dramatic GAAP EPS recovery Risk: If Q4 2024 comes in below the easy comp (organic < 7%), it suggests permanent customer loss is worse than expected Catalyst significance: Medium — widely anticipated, largely priced in; magnitude matters
Catalyst 3: Henry Schein One (HSOne) ARR Disclosure
Timeline: FY2024 investor day or Q4 earnings What to watch: First detailed HSOne ARR disclosure (management has been somewhat opaque about HSOne financials) Bull case: HSIC separately reports HSOne ARR of $700M+, growing 12-15%; commands a 20-25x ARR multiple (implies $14-17.5B valuation for software alone — vs. HSIC's entire ~$9B market cap) Bear case: HSOne growth below 10%, churn rising due to Fuse/cloud competition; management avoids specific disclosure Probability: Management was reportedly considering an HSOne investor day as of 2024; any concrete ARR disclosure would be significant
Catalyst 4: DSO Strategic Announcements / Contract Wins
Timeline: Rolling, any quarter What to watch: Multi-year preferred supplier agreements with top-20 DSOs; HSOne enterprise deals Magnitude: A single contract with Heartland Dental (1,700 locations) for HSOne across all locations could add ~$10-15M incremental ARR Why it matters: Institutional investors are watching whether DSO adoption of HSOne validates the software strategy
Catalyst 5: Strategic Review / HSOne Separation
Timeline: 2-3 year horizon (medium-term) What to watch: Activist pressure or board-initiated review of separating HSOne from the distribution business Precedent: McKesson spun off Change Healthcare; Cardinal separated specialty pharma businesses Value case: A standalone HSOne business at SaaS multiples (~20-25x EBITDA) vs. the current blended distribution multiple (~11-12x) would create significant value Probability: 15-20% within 3 years; activist interest in HSIC has been rumored Potential share price impact: +$20-35/share if separation announced
Catalyst 6: Acquisition of Specialty Dental Asset
Timeline: 12-24 months What to watch: A major specialty dental acquisition (implants, orthodontics, or digital workflow platform) Historical precedent: Hu-Friedy ($425M, 2019) added high-margin premium instruments; strategic dental software acquisitions add HSOne capability Positive scenario: HSIC acquires a high-growth specialty dental software company (e.g., an orthodontic workflow platform) at reasonable multiples, accelerating HSOne's specialty penetration Negative scenario: HSIC overpays for an acquisition at a peak valuation, destroying capital
Catalyst 7: Macro Dental Volume Recovery
Timeline: FY2025-2026 What to watch: ADA dental utilization surveys; practice revenue data from dental group practice consolidators (Henry Schein One has visibility) Bull trigger: Post-pandemic catch-up demand (deferred implants, orthodontics) + dental benefits expansion drives 5-6% market growth → dental segment organic revenue growth 6-8% Bear trigger: US recession → elective procedure deferrals → dental market contracts 2-3%
Bull Case
Bull Case
- Cyber legal resolution removes the ~$50-75M annual cost overhang and the valuation multiple discount, driving EPS recovery to $6.00+ by FY2026 while an HSOne ARR disclosure unlocks a re-rating from 12x to 16x earnings
- Henry Schein One's 300,000+ practitioner installed base and 2-3% churn rate represents a growing, high-ROIC software annuity that the market is materially undervaluing at the current blended distribution multiple, with ARR growth accelerating as HSOne expands into RCM, patient financing, and DSO enterprise software
- DSO consolidation (now ~40% of US dental) accelerates HSIC's position as the preferred enterprise dental partner — providing scale-driven volume growth, higher HSOne attach rates, and a structural competitive moat that smaller rivals cannot replicate
Bear Case
- Ongoing cyber-related legal liability (HIPAA penalties, class actions) exceeds insurance coverage and drags EPS materially below consensus for 3+ years while permanently damaging customer trust and accelerating defection to Patterson and online channels
- Patterson's Fuse cloud-native practice management software erodes Dentrix/Eaglesoft's installed base meaningfully over 3-5 years, compressing HSOne's premium growth narrative and forcing HSIC to accept lower subscription pricing to defend customer retention
- DSO consolidation creates concentrated pricing pressure on HSIC's core consumables and equipment business, structurally compressing gross margins from 35% to 33-34% over the next 5 years while the distribution competitive moat erodes as manufacturers increasingly sell equipment direct to large DSO groups
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.